

# Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

# Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

## SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

# Product Information



### **KRN 7000**

Item No. 11208

CAS Registry No.: Formal Name:	158021-47-7 N-[(1S,2S,3R)-1-[(α-D-	ОН	
	galactopyranosyloxy)methyl]-2,3- dihydroxyheptadecyl]-hexacosanamide	но	
MF:	$C_{50}H_{99}NO_{9}$		
FW:	858.3	0	Y Y
Purity:	≥96%		Д Д он
Stability:	≥1 year at -20°C	HO	$\sim$
Supplied as:	An off-white solid		ÓН

#### Laboratory Procedures

For long term storage, we suggest that KRN 7000 be stored as supplied at -20°C. It should be stable for at least one year. KRN 7000 is supplied as a crystalline solid. It is sparingly soluble in organic solvents such as tetrahydrofuran and pyridine.

KRN 7000 is a potent synthetic  $\alpha$ -galactosylceramide, which, in association with the antigen-presenting CD1d protein, activates NKT immune cells.<sup>1,2</sup> As these cells have important roles in the rejection of malignant tumors and in the regulation of several autoimmune diseases, KRN 7000 has activity in many diseases, including cancer, lupus, diabetes, malaria, and tuberculosis.3-5

#### References

- 1. Van Der Vliet, H.J.J., Nishi, N., Koezuka, Y., et al. Effects of α-galactosylceramide (KRN 7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Va24<sup>+</sup> VB11<sup>+</sup> T cells. Immunology 98, 557-563 (1999).
- Nicol, A., Nieda, M., Koezuka, Y., *et al.* Human invariant  $V\alpha 24^+$  natural killer T cells activated by  $\alpha$ -galactosylceramide (KRN 7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 99, 229-234 (2000).
- Morita, M., Motoki, K., Akimoto, K., et al. Structure-activity relationship of  $\alpha$ -galactosylceramides against B16-3. bearing mice. J. Med. Chem. 38, 2176-2187 (1995).
- Nakagawa, R., Motoki, K., Ueno, H., et al. Treatment of hepatic metastasis of the Colon26 adenocarcinoma with an α-galactosylceramide, KRN 7000. Cancer Res. 58, 1202-1207 (1998).
- 5. Banchet-Cadeddu, A., Hénon, E., Dauchez, M., et al. The stimulating adventure of KRN 7000. Org. Biomol. Chem. 9, 3080-3104 (2011).

#### **Related Products**

For a list of related products please visit: www.caymanchem.com/catalog/11208

#### **Cayman Chemical**

#### **Mailing address**

1180 E. Ellsworth Road Ann Arbor, MI 48108 USA

Phone (800) 364-9897 (734) 971-3335

Fax (734) 971-3640

#### E-Mail

custserv@caymanchem.com

#### Web

www.caymanchem.com

WARNING: This product is for laboratory research only: not for administration to humans. Not for human or veterinary DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes no warranty or guarantee of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

at the time of delivery. Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence. This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees. Buyer's exclusive **remedy** and Cayman's sole liability hereunder shall be limited to a <u>refund</u> of the purchase price, or at Cayman's option, the <u>replacement</u>, at no cost to Buyer, of all material that does not meet our specifications. Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material. **For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.** Copyright Cayman Chemical Company, 11/06/2014